Elisrasib monotherapy delivers an ORR of 78.0% and median PFS of 12.4 months in first-line KRAS G12...
Elisrasib monotherapy demonstrates notable efficacy in three major tumor types at its recommended p...
SHANGHAI, March 20, 2026 /PRNewswire/ -- D3 Bio Inc, a global clinical-stage biotechnology company ...
SHANGHAI, Jan. 19, 2026 /PRNewswire/ -- D3 Bio, a global clinical‑stage biotechnology company focus...
SHANGHAI, Dec. 10, 2025 /PRNewswire/ -- D3 Bio, a global clinical-stage biotechnology company focus...
* Breakthrough Therapy Designation was granted for the treatment of adult patients with KRAS G12C...